Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19529
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMohan, R. R.en
dc.contributor.authorChalla, A.en
dc.contributor.authorGupta, S.en
dc.contributor.authorBostwick, D. G.en
dc.contributor.authorAhmad, N.en
dc.contributor.authorAgarwal, R.en
dc.contributor.authorMarengo, S. R.en
dc.contributor.authorAmini, S. B.en
dc.contributor.authorParas, F.en
dc.contributor.authorMacLennan, G. T.en
dc.contributor.authorResnick, M. I.en
dc.contributor.authorMukhtar, H.en
dc.date.accessioned2015-11-24T19:00:25Z-
dc.date.available2015-11-24T19:00:25Z-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19529-
dc.rightsDefault Licence-
dc.subjectBiological Markers/analysisen
dc.subjectBody Fluids/*enzymologyen
dc.subjectHumansen
dc.subjectImmunoblottingen
dc.subjectMaleen
dc.subjectOrnithine Decarboxylase/*biosynthesis/metabolismen
dc.subjectProstate/*enzymologyen
dc.subjectProstatic Hyperplasia/enzymologyen
dc.subjectProstatic Neoplasms/*enzymologyen
dc.titleOverexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humansen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9918212-
heal.identifier.secondaryhttp://clincancerres.aacrjournals.org/content/5/1/143.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1999-
heal.abstractProstate cancer (PCA), the most commonly diagnosed cancer in males in the United States, is the second leading cause of cancer-related deaths of males in this country. Because of the poor success rate in the treatment of PCA, an intervention at an early stage may reduce the progression of small carcinoma to large metastatic lesion, thereby reducing PCA-related deaths. Concerted efforts are needed to establish mechanism-based approaches to develop: (a) the markers for early detection of the disease as well as toward monitoring the efficacy of treatment(s); and (b) novel chemopreventive strategies against PCA. Using unique samples of pair-matched benign and cancer tissue obtained from the same PCA patient, we showed that ornithine decarboxylase (ODC) activity is significantly (P < 0.001) elevated in PCA (1142 +/- 100; mean +/- SE) than in paired benign tissue (427 +/- 51; mean +/- SE). The immunoblot analysis also showed a significant elevation in the protein expression of ODC in the PCA tissues as compared with the paired benign tissue. Furthermore, our data showed that the ODC activity in the prostatic fluid obtained by a digital rectal massage from the patients with PCA (3847 +/- 162; mean +/- SE) was significantly higher than in the patients with benign prostatic hyperplasia (2742 +/- 167; mean +/- SE) or normal individuals (1244 +/- 67; mean +/- SE). This observation might be of significance because the prostatic fluid could be obtained noninvasively by digital rectal massage. We suggest that ODC could serve as a target for early detection of human PCA as well as for monitoring the efficacy of treatment(s). The development of ODC as a target for novel chemopreventive strategies against PCA is an intriguing possibility.en
heal.journalNameClin Cancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Mohan-1999-Overexpression of or.pdf141.49 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons